Advisers to the U.S. Food and Drug Administration will consider whether to recommend Novavax Inc.’s COVID-19 vaccine for adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics.
The U.S. Food and Drug Administration (FDA) is on a mission to recover from the review lag seen through the early years of COVID-19 and has issued special designations for two treatments that could improve the lives of millions diagnosed with recurrent glioblastoma or hemophilia.
COVID-19 cases in the Americas increased 10.4 percent last week from the previous one, but countries must also pay attention to a rise in other respiratory viruses in the region, the Pan American Health Organization (PAHO) said on Wednesday.
Use of Pfizer Inc.’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.
The World Health Organization’s governing board agreed on Monday to form a new committee to help speed up its response to health emergencies like COVID-19.
Countries have agreed to an initial U.S.-led push to reform the rules around disease outbreaks, known as the International Health Regulations, after early opposition from Africa and others was overcome this week, sources told Reuters on Friday.
As cases and news of monkeypox spread globally, scientists are investigating the unprecedented outbreak. BioSpace compiled updates about tracking, origins and treatments concerning monkeypox.
Patients who experience recurrence of COVID-19 symptoms after completing treatment with Pfizer’s drug Paxlovid should isolate again for five days, the U.S. Centers for Disease Control and Prevention said in an advisory issued on Tuesday.
North Korea on May 21 reported more than 200,000 new patients suffering from fever for a fifth consecutive day, as the country fought its first confirmed coronavirus outbreak.
Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86 percent of genomics studies to date have involved people of European ancestry, which has limited the potential benefits of genomic research for many populations. Rebecca Sutphen, Co-Founder and Chief Medical Officer of InformedDNA, and Board-Certified Genetic Counselor Karmen Trzupek analyze strategies to increase diversity in rare genetic disease trials.